ESOMAR-certified company Future Market Insights (FMI) has published a report on the global pharmacovigilance market for the forecast period 2021-2031. According to the report, the market is poised to reach new heights, as pharmaceutical companies scramble to introduce new drug candidates for multiple ailments, which will result in an increase in clinical trials.
As per FMI’s analysis, the market is expected to register double-digit growth, experiencing an impressive CAGR throughout the forecast period. Historically, the market posted credible gains, surpassing US$ 6 billion in 2020, expanding at a CAGR of over 14%. Growth prospects were further heightened during the COVID-19 pandemic, as the scramble for new treatment approaches is prompting pharmaceutical companies to initiate clinical trials for the same.
Prominent pharmaceutical companies are forging long-term partnerships and service agreements with contract research organizations and business processing outsourcing units to enhance existing pharmacovigilance operations by virtue of cost reduction from drug delivery to post-marketing approvals. In April 2021, Thermo Fisher Scientific Inc. announced its plans to acquire Pharmaceutical Product Development (PPD) Inc. for a purchase price of US$ 17.4 billion, which will help enhance the latter’s pharmacovigilance portfolio expansion.
Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-1107
On the basis of service providers, the market has been segmented into in-house and contract outsourcing. As the number of chemical entities has been growing in the global pharmaceuticals market, pharmacovigilance is increasingly become a mandate for drug manufacturers. Considering the change in regulations, phase III and phase IV studies are being increasingly conducted to monitor the long-term safety outcomes of pharmaceuticals and biological products. Implementation of active pharmacovigilance activities assists in the execution of long-term plans, such as in bringing improvement in patient outcome and minimisation of health care associated costs, particularly related to Adverse Drug Reactions (ADRs), and in the prevention of drug hazards.
To provide deeper insights into the pharmacovigilance market, the report has also been segmented by phase of drug development, type of reporting method and type of service provider.
By phase of drug development, the clinical trial phase III segment is projected to expand at a CAGR of 15.5% in the global pharmacovigilance market by phase of drug development by 2020 end in terms of value. Evaluation of real-time effectiveness of the drug and availability of a facility to conduct trials in state-of-the-art settings, thus complementing the outcomes of premarketing randomised control trials, are the prime benefits availed from pharmacovigilance in phase IV trials. It has also been reported that approximately 57% of the global pharmaceutical companies outsource post marketing operations to CROs in order to avoid the high operational cost associated with technological infrastructure and hiring skilled staff.
Our advisory services are aimed at helping you with specific, customised insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-1107
The primary barriers in the market include high risk associated with securing data in case of pharmacovigilance outsourcing and lack of availability of skilled workforce specialising in drug monitoring.
The primary trend in the pharmacovigilance market is an increase in dependence on third party services. Other trends include harnessing shorter turnaround times for faster market capitalisation and requirement of highly skilled personnel for monitoring side effects.
Some of the key players identified in the global pharmacovigilance market report include: Accenture plc, Bristol-Myers Squibb, Clinquest Group B.V., Cognizant Technology Solutions, Covance, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc (GSK), ICON plc, iGATE Corporation, iMEDGlobal Corporation, inVentiv Health, Inc., Novartis International AG, PAREXEL International Corporation, Pfizer, Inc., Pharmaceutical Product Development, LLC. (PPD), PRA Health Sciences, Inc., Quintiles Transnational Holdings, Inc., Sanofi S.A., Synowledge LLC and Wipro Limited. These companies specialise in pharmacovigilance services, and focus on market consolidation initiatives and analyses of their specific strengths, weaknesses, opportunities and threats to strengthen their position in the market.
The report has been concluded with strategic recommendations for players already present in the market and new players planning to enter the market, which could help them in the near future.
This report assesses factors driving growth of each segment of the market and presents analysis and key insights on the potential of the pharmacovigilance market as per region-specific trends. North America accounted for majority of the pharmacovigilance market revenue in 2014. However, incidences of increasing consumption of drugs and rise in cases of adverse drug reactions are expected to drive growth of the market in Asia Pacific and Latin American regions.
Preview Analysis Global Pharmacovigilance Market Segmentation By Phase Of Drug Development (Preclinical Studies, Phase I, Phase II, Phase III, Phase IV); By Methods (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining); By Type Service Provider (In-House, Contract Outsourcing), Others – Market Size, Growth, Forecast, Sales, Pricing Forecast, Share, Export Value, Export Volume, Trade: https://www.futuremarketinsights.com/reports/pharmacovigilance-market
More from FMI’s Healthcare, Pharmaceuticals and Medical devices Intelligence:
- Allergy Diagnostics Market Segmentation Product Type – Assay Kits, Instruments, Consumables, Services; End User – Diagnostic Laboratories, Hospital, Academic Research Institutes, Others; Allergen Type – Inhaled Allergens, Food Allergens, Drug Allergens, Other Allergens; Test Type – In-vivo, In-vitro: https://www.futuremarketinsights.com/reports/allergy-diagnostics-market
- Pharmaceutical Filtration Market Segmentation Product Type – Membrane Filters, Prefilters and Depth Media Filters, Single-use Systems, Cartridge & Capsule Filters, Filter Holders, Filtration Accessories, Other Products; Scale of Operation – Manufacturing Scale, Pilot Scale, R&D Scale; Application – Final Product Processing, Raw Material Filtration, Cell Separation, Water Purification, Air Purification; Technology – Microfiltration, Ultrafiltration, Nanofiltration, Other techniques: https://www.futuremarketinsights.com/reports/pharmaceutical-filtration-market
- Vascular Closure Device (VCD) Market Segmentation Product Type – Haemostasis Pads, Compression Devices, Clip, Plug, Suture, Others; End User – Hospitals, Ambulatory Surgical Centres, Independent Catheterisation Labs: https://www.futuremarketinsights.com/reports/vascular-closure-devices-market